Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: A pilot study in 15 patients

American Journal of Ophthalmology

Volumn 154, Issue 3, 2012, Pages

  Markomichelakis, Nikos ^a   Delicha, Evie ^b   Masselos, Stylianos ^a   Sfikakis, Petros P ^b  

^a IASO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ADULT; ANTERIOR EYE CHAMBER; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EYE INFLAMMATION; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; PILOT STUDY; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RETINA MACULA CYSTOID EDEMA; RETINA VASCULITIS; RETINITIS; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL ACUITY; VITREOUS BODY;

EID: 84865817759     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.03.035     Document Type: Article

References (34)

1. P.P. Sfikakis The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future Curr Dir Autoimmun 11 2010 180 210
2. P.G. Theodossiadis, N.N. Markomichelakis, P.P. Sfikakis Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation Retina 27 4 2007 399 413
3. N.N. Markomichelakis, P.G. Theodossiadis, P.P. Sfikakis Regression of neovascular age-related macular degeneration following infliximab therapy Am J Ophthalmol 139 3 2005 537 540
4. P.P. Sfikakis, V. Grigoropoulos, I. Emfietzoglou Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study Diabetes Care 33 7 2010 1523 1528
5. Y. Yazici, S. Yurdakul, H. Yazici Behçet's syndrome Curr Rheumatol Rep 12 6 2010 429 435
6. R.O. Kacmaz, J.H. Kempen, C. Newcomb Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity Am J Ophthalmol 146 6 2008 828 836
7. N. Kitaichi, A. Miyazaki, D. Iwata, S. Ohno, M.R. Stanford, H. Chams Ocular features of Behçet's disease: an international collaborative study Br J Ophthalmol 91 12 2007 1579 1582
8. I. Tugal-Tutkun, S. Onal, R. Altan-Yaycioglu, H. Huseyin Altunbas, M. Urgancioglu Uveitis in Behçet disease: an analysis of 880 patients Am J Ophthalmol 138 13 2004 373 380
9. S. Tuncer, S. Yilmaz, M. Urgancioglu, I. Tugal-Tutkun Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease J Ocul Pharmacol Ther 23 4 2007 395 401
10. P.P. Sfikakis, P.G. Theodossiadis, C.G. Katsiari, P. Kaklamanis, N.N. Markomichelakis Effect of infliximab on sight-threatening panuveitis in Behçet's disease Lancet 358 9278 2001 295 296
11. N. Markomichelakis, E. Delicha, S. Masselos, K. Fragiadaki, P. Kaklamanis, P.P. Sfikakis A single infliximab infusion versus corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study Rheumatology (Oxford) 50 3 2011 593 597
12. A. Arida, K. Fragiadaki, E. Giavri, P.P. Sfikakis Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients Semin Arthritis Rheum 41 1 2011 61 70
13. G. Hatemi, A. Silman, D. Bang EULAR Expert Committee EULAR recommendations for the management of Behçet disease Ann Rheum Dis 67 12 2008 1656 1662
14. M. Diaz-Llopis, S. García-Delpech, D. Salom High-dose infliximab prophylaxis in endotoxin-induced uveitis J Ocul Pharmacol Ther 23 4 2007 343 350
15. J.L. Olson, R.J. Courtney, N. Mandava Intravitreal infliximab and choroidal neovascularization in an animal model Arch Ophthalmol 125 9 2007 1221 1224
16. F. Giansanti, M. Ramazzotti, L. Vannozzi A pilot study on ocular safety of intravitreal infliximab in a rabbit model Invest Ophthalmol Vis Sci 49 3 2008 1151 1156
17. F. Giansanti, M. Ramazzotti, M. Giuntoli Intravitreal infliximab clearance in a rabbit model: different sampling methods and assay techniques Invest Ophthalmol Vis Sci 50 11 2009 5328 5335
18. P.G. Theodossiadis, V.S. Liarakos, P.P. Sfikakis Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit Graefes Arch Clin Exp Ophthalmol 247 2 2009 273 281
19. C.V. Regatieri, J.L. Dreyfuss, G.B. Melo, D. Lavinsky, M.E. Farah, H.B. Nader Dual role of intravitreous infliximab in experimental choroidal neovascularization: effect on the expression of sulfated glycosaminoglycans Invest Ophthalmol Vis Sci 50 11 2009 5487 5494
20. H. Hosseini, A. Safaei, M.R. Khalili Intravitreal infliximab in experimental endotoxin-induced uveitis Eur J Ophthalmol 19 5 2009 818 823
21. Standardization of uveitis nomenclature for reporting clinical data Results of the first international workshop J Ophthalmol 140 3 2005 509 516
22. D. BenEzra, J.V. Forrester, R.B. Nussenblatt, K. Tabbara, P. Timonen Uveitis Scoring System 1991 Springer Verlag Berlin
23. P.P. Sfikakis, P. Kaklamanis, A. Elezoglou Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet's disease Ann Intern Med 140 5 2004 404 406
24. International Study Group for Behçet's Disease Criteria for diagnosis of Behçet's disease Lancet 335 8697 1990 1078 1080
25. M. Giganti, P.M. Beer, N. Lemanski, C. Hartman, J. Schartman, N. Falk Adverse events after intravitreal infliximab (Remicade) Retina 30 1 2010 71 80
26. A. Elezoglou, N. Kafasi, P.H. Kaklamanis Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease Clin Exp Rheumatol 25 4 Suppl 45 2007 S65 S69
27. J.S. Pulido, J.E. Pulido, C.J. Michet, R.G. Vile More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial Retina 30 1 2010 1 5
28. P.G. Theodossiadis, V.S. Liarakos, P.P. Sfikakis, I.A. Vergados, G.P. Theodossiadis Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration Am J Ophthalmol 147 5 2009 825 830
29. L. Arias, J.M. Caminal, M.B. Badia, M.J. Rubio, J. Catala, O. Pujol Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy Retina 30 10 2010 1601 1608
30. M. Farvardin, M. Afarid, M. Mehryar, H. Hosseini Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis Retina 30 9 2010 1530 1535
31. L. Wu, E. Hernandez-Bogantes, J.A. Roca, J.F. Arevalo, K. Barraza, A.F. Lasave Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group Retina 31 2 2011 298 303
32. G.B. Melo, M.N. Moraes Filho Toxicity and retinal penetration of infliximab in primates Retina 32 3 2012 606 612
33. N.N. Markomichelakis, P.G. Theodossiadis, E. Pantelia, S. Papaefthimiou, G.P. Theodossiadis, P.P. Sfikakis Infliximab for chronic cystoid macular edema associated with uveitis Am J Ophthalmol 138 4 2004 648 650
34. P.P. Sfikakis, G. Tsokos Towards the next generation of anti-TNF drugs Clin Immunol 141 3 2011 231 235